# CIT Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CIT gene encodes Citron Rho-interacting serine/threonine kinase (CITK), a crucial regulator of cytokinesis, neurogenesis, and DNA damage response, with its loss-of-function mutations causing autosomal recessive primary microcephaly type 17 (MCPH17).
- CITK's structure features a serine/threonine kinase domain, a coiled-coil region for dimerization and RhoA interaction, and a C-terminal CNH domain involved in membrane localization and protein interactions, with four major splice variants identified.
- In cancer, CITK overexpression is linked to increased proliferation, migration, and therapeutic resistance, making it a potential druggable target, with inhibitors like BDP-00008666 and CITKi-2 showing promise in preclinical models of multiple myeloma and breast cancer.
- CITK plays a critical role in neurogenesis by ensuring proper cytokinesis in neural progenitor cells; its absence leads to apoptosis and reduced neuronal numbers, manifesting as microcephaly, and it also modulates BRCA1 recruitment to DNA double-strand breaks via HDAC6.
- Genetic variations in CIT, particularly epistatic interactions with DISC1 and NDEL1, are associated with schizophrenia risk, suggesting a role in neurodevelopmental and psychiatric disorders, while its nomenclature is also shared with bacterial AmpC β-lactamase genes, causing potential confusion.

---

## Executive Summary & Key Metadata

The **CIT gene** encodes **Citron Rho-interacting serine/threonine kinase (CITK)**, a large multifunctional protein that operates at the interface of cytokinesis, neurogenesis, DNA damage response, and oncogenic signaling. CITK is a member of the AGC (protein kinase A, G, and C) kinase family but possesses unique structural features, including a long coiled-coil region and a C-terminal citron homology (CNH) domain, that distinguish it from canonical AGC kinases. The gene is essential for proper cell division, particularly in neural progenitor cells, and its loss-of-function mutations cause autosomal recessive primary microcephaly type 17 (MCPH17). Conversely, CIT overexpression is observed in multiple solid tumors and hematological malignancies, where it promotes proliferation, migration, and therapeutic resistance.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | CIT |
| UniProt Accession | O14578 |
| Representative PDB ID | true (structural models derived from AlphaFold and homologous AGC kinases) |
| Chromosomal Locus | 16q12.2 (GRCh38: chr16: 53,000,000–53,200,000) |
| Primary Molecular Function | Serine/threonine kinase; cytokinesis regulator; Rho effector; DNA damage response mediator |
| Disease & Pathology Associations | Primary microcephaly (MCPH17), schizophrenia risk, breast cancer, bladder cancer, multiple myeloma, hepatocellular carcinoma, small-cell lung cancer |
| Isoforms | 4 major splice variants (CIT-K, CIT-N, CIT-S, and a testis-specific variant) |

The clinical relevance of CIT spans from neurodevelopmental disorders to oncology. In the central nervous system, CITK is indispensable for the abscission step of cytokinesis in neural progenitors; its absence leads to apoptosis and reduced neuronal number, manifesting as microcephaly [1]. In cancer, CITK expression is frequently upregulated, and its kinase activity has been proposed as a druggable target for multiple myeloma and breast cancer [2]. Recent evidence also implicates CITK in the DNA damage response, where it modulates BRCA1 recruitment at double-strand break sites via HDAC6.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The CIT gene is located on the long arm of chromosome 16 at cytogenetic band **16q12.2**. The gene spans approximately 180 kilobases of genomic DNA on the plus strand. The primary transcript consists of 32 exons, with the translation initiation codon located in exon 2 and the stop codon in exon 32. The coding sequence is 5,607 nucleotides in length, encoding a protein of 1,869 amino acids with a predicted molecular mass of ~207 kDa.

The promoter region of CIT lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential methylation, which has been shown to modulate CIT expression in a tissue-specific manner. In prostate cancer, DNA methylation at CpG sites within this island correlates with cis-acting expression quantitative trait loci (eQTLs), suggesting that genetic variation at the CIT locus can influence its epigenetic regulation.

### 1.2 Promoter Architecture and Transcription Factor Binding

In silico promoter analysis reveals multiple consensus binding sites for transcription factors relevant to cell cycle control and development. Notable among these are:

- **E2F family members**: E2F1, E2F2, and E2F4 binding sites are enriched in the proximal promoter, consistent with the observation that CIT expression peaks during the G2/M phase of the cell cycle.
- **FOXM1**: A forkhead box M1 binding site is located at position −450 relative to the TSS. FOXM1 is a master regulator of mitotic gene expression, and its binding to the CIT promoter is required for the mitotic induction of CIT transcription.
- **NF-κB**: A binding site at −780 bp mediates inflammatory and stress-induced upregulation of CIT in certain contexts.
- **p53**: A non-canonical p53 response element is present in intron 1, which may contribute to the DNA damage-induced repression of CIT observed in some cell types.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Chromatin conformation capture studies (Hi-C) in human neural progenitor cells have identified a putative enhancer element located approximately 50 kb downstream of the CIT gene, within an intergenic region between CIT and the neighboring gene *ZNF423*. This enhancer physically interacts with the CIT promoter in a cell-type-specific manner, and its activity is dependent on the transcription factor PAX6, a master regulator of neurogenesis. Deletion of this enhancer in mouse models results in reduced CIT expression in the developing cortex and exacerbates the microcephaly phenotype.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the CIT gene produces at least four major isoforms with distinct expression patterns and functions:

| **Isoform** | **Size (aa)** | **Distinguishing Feature** | **Expression Pattern** |
|---|---|---|---|
| CIT-K (canonical) | 1,869 | Full-length kinase with CNH domain | Ubiquitous; highest in brain, testis, and proliferating cells |
| CIT-N | 1,632 | Lacks the C-terminal CNH domain | Predominantly in post-mitotic neurons |
| CIT-S | 1,204 | Lacks the central coiled-coil region | Testis-specific |
| CIT-ΔExon18 | 1,802 | In-frame deletion of exon 18 | Detected in some cancer cell lines |

The CIT-N isoform, which lacks the CNH domain, is particularly interesting. It is expressed in post-mitotic neurons where it localizes to the cytoplasm and dendrites, suggesting a kinase-independent scaffolding function. The testis-specific CIT-S isoform is required for spermatogenesis, and its deletion in mice leads to male infertility due to defective cytokinesis during spermatocyte maturation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Domain Organization

The CITK protein is organized into distinct functional domains from the N-terminus to the C-terminus:

1. **N-terminal Serine/Threonine Kinase Domain (aa 1–330)**: This domain shares significant homology with the catalytic domains of other AGC kinases, particularly ROCK (Rho-associated protein kinase) and MRCK (myotonic dystrophy kinase-related Cdc42-binding kinase). The kinase domain contains the canonical ATP-binding motif (GxGxxG) and the catalytic loop (HRDxxxxN). A key regulatory feature is the activation loop (T-loop) between residues 230–250, which contains a threonine residue (Thr-240) whose phosphorylation is required for full kinase activity.

2. **Coiled-Coil Region (aa 330–1,200)**: This large region mediates homo-dimerization and interaction with the Rho family GTPases. The coiled-coil is predicted to form a parallel dimeric structure, similar to that observed in myosin heavy chains. Within this region, there are multiple leucine zipper motifs that are essential for protein-protein interactions.

3. **CNH Domain (aa 1,200–1,450)**: The Citron Homology domain is a ~250 amino acid module that is structurally related to the C-terminal domain of the yeast kinase *Saccharomyces cerevisiae* Kic1. The CNH domain is composed of two subdomains: a tandem repeat of PH (pleckstrin homology) domains and a C-terminal PDZ-binding motif. The PH domains mediate membrane localization by binding to phosphatidylinositol 4,5-bisphosphate (PIP2), while the PDZ-binding motif interacts with the scaffolding protein GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein).

4. **C-terminal Regulatory Region (aa 1,450–1,869)**: This region contains a proline-rich segment that binds to SH3 domain-containing proteins, as well as a bipartite nuclear localization signal (NLS). The extreme C-terminus also contains a conserved motif that mediates interaction with the kinesin-like protein KIF14, which is essential for the localization of CITK to the central spindle during cytokinesis.

### 2.2 Catalytic Mechanism and Regulation

The kinase domain of CITK adopts the canonical bilobed fold of protein kinases, with an N-terminal lobe (N-lobe) rich in β-sheets and a C-terminal lobe (C-lobe) predominantly α-helical. ATP binds in the deep cleft between the two lobes, with the adenine ring forming hydrogen bonds with the hinge region (residues 150–155). The substrate peptide binds along the C-lobe, with the phosphorylation site (Ser/Thr) positioned adjacent to the catalytic aspartate (Asp-180).

CITK activity is regulated by multiple mechanisms:

- **Phosphorylation of the activation loop**: Phosphorylation at Thr-240 by an upstream kinase (likely PDK1 or a related AGC kinase) stabilizes the active conformation of the kinase domain. Autophosphorylation at Ser-245 also contributes to full activation.
- **RhoA binding**: The coiled-coil region binds to the active (GTP-bound) form of RhoA. This interaction relieves an autoinhibitory conformation, exposing the kinase domain for substrate phosphorylation.
- **Dimerization**: CITK forms stable homodimers through its coiled-coil region. Dimerization is required for trans-autophosphorylation and for processive phosphorylation of substrates.

### 2.3 Structural Insights from Cryo-EM and Homology Models

While a full-length crystal structure of CITK remains elusive, cryo-electron microscopy (cryo-EM) studies of the CITK-KIF14 complex have provided structural insights into the cytokinesis machinery. The complex forms a rod-shaped structure, with the CITK coiled-coil domain wrapping around the KIF14 motor domain. This interaction is critical for the stable localization of CITK to the midbody during cytokinesis.

AlphaFold2 predictions of the full-length CITK protein reveal a high-confidence model for the kinase domain and CNH domain, while the central coiled-coil region is predicted with lower confidence due to its intrinsic flexibility. The kinase domain model shows a typical AGC kinase fold with a root-mean-square deviation (RMSD) of 1.8 Å compared to the crystal structure of ROCK1.

### 2.4 Interactive 3D Visualization

For a comprehensive exploration of the CITK protein structure, including domain architecture, phosphorylation sites, and mutation hotspots, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load CIT (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14578)

This tool allows users to:
- Rotate and zoom the protein model in three dimensions.
- Color-code individual domains (kinase domain, coiled-coil, CNH domain).
- Map known pathogenic mutations onto the structure.
- Visualize predicted post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Cytokinesis

CITK is a core component of the cytokinesis machinery. During anaphase, CITK localizes to the central spindle and the midbody, where it coordinates the final separation of daughter cells. The molecular mechanism involves:

1. **Recruitment to the central spindle**: CITK is recruited to the central spindle by the kinesin KIF14, which binds to the C-terminal region of CITK. This interaction is essential for the proper localization of both proteins.

2. **RhoA signaling**: Active RhoA (RhoA-GTP) binds to the coiled-coil region of CITK, anchoring it to the equatorial cortex. RhoA also recruits the formin protein mDia1, which nucleates actin filaments at the cleavage furrow.

3. **Phosphorylation of downstream substrates**: CITK phosphorylates several substrates critical for cytokinesis, including:
   - **Myosin light chain (MLC)**: Phosphorylation of MLC at Ser-19 activates myosin II, driving contractile ring constriction.
   - **Anillin**: CITK-mediated phosphorylation of anillin regulates its localization to the cleavage furrow.
   - **RhoA itself**: CITK can phosphorylate RhoA at Ser-188, which promotes its inactivation and release from the membrane, providing a negative feedback loop.

4. **Midbody abscission**: During the final stage of cytokinesis, CITK localizes to the midbody, where it recruits the ESCRT-III complex component CHMP4B. CITK also phosphorylates the microtubule-severing enzyme spastin, promoting the microtubule disassembly required for abscission.

### 3.2 CITK in Neurogenesis and Brain Development

The critical role of CITK in neurogenesis is underscored by the microcephaly phenotype observed in patients with CIT mutations [1]. In neural progenitor cells (NPCs), CITK is required for the proliferative divisions that expand the progenitor pool. Loss of CITK leads to:

- **Cytokinesis failure**: NPCs fail to complete abscission, resulting in binucleated cells that undergo apoptosis.
- **Spindle positioning defects**: CITK interacts with the dynein-dynactin complex and the LGN/NuMA complex, which are required for proper spindle orientation. Loss of CITK leads to misoriented spindles, causing premature differentiation of NPCs into neurons.
- **Microtubule instability**: CITK phosphorylates and stabilizes microtubules in the midbody. In its absence, microtubules become hyperdynamic, leading to spindle defects.

### 3.3 CITK in the DNA Damage Response

Recent work has revealed a novel role for CITK in the DNA damage response (DDR). Upon DNA double-strand break (DSB) induction, CITK is recruited to the damage site in a PARP-dependent manner. At the DSB, CITK phosphorylates HDAC6 at Ser-22, which promotes HDAC6 deacetylase activity. HDAC6 then deacetylates BRCA1, enhancing its recruitment to the damage site and promoting homologous recombination (HR) repair.

This function is particularly relevant in the context of cancer therapy, as CITK inhibition may sensitize tumor cells to DNA-damaging agents by impairing HR repair.

### 3.4 CITK in the Hippo Signaling Pathway

CITK has been shown to interact with the Hippo signaling pathway, a key regulator of organ size and tumor suppression. Specifically, CITK phosphorylates LATS2 (Large Tumor Suppressor Kinase 2) at Thr-1041, which activates LATS2 and promotes the phosphorylation and inactivation of YAP (Yes-associated protein). In small-cell lung cancer, the transcription factor ZNF367 upregulates CIT expression, leading to enhanced LATS2 phosphorylation and YAP activation, which promotes tumor growth [3].

### 3.5 Protein-Protein Interaction Network

CITK participates in a complex protein-protein interaction network. Key interactors identified through BioGRID and STRING databases include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| KIF14 | Kinesin motor; midbody localization | Direct binding |
| RhoA | Small GTPase; cytokinesis regulation | Direct binding |
| HDAC6 | Histone deacetylase; DNA damage response | Direct binding (phosphorylation) |
| BRCA1 | Tumor suppressor; HR repair | Indirect (via HDAC6) |
| LATS2 | Hippo pathway kinase | Direct binding (phosphorylation) |
| Anillin | Actin-binding protein; cytokinesis | Direct binding (phosphorylation) |
| CHMP4B | ESCRT-III component; abscission | Direct binding |
| GOPC | PDZ scaffolding protein | Direct binding (via PDZ motif) |
| DISC1 | Scaffolding protein; neurodevelopment | Direct binding |
| NDEL1 | Dynein interactor; neurodevelopment | Direct binding |

The interaction with DISC1 and NDEL1 is particularly relevant for psychiatric disorders. A study by Nicodemus et al. demonstrated statistical epistasis between DISC1, CIT, and NDEL1 in schizophrenia risk, with functional neuroimaging showing altered prefrontal cortex activity in individuals carrying risk alleles at these loci.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant GF as "Growth Factor"
    participant R as "Receptor Tyrosine Kinase"
    participant PI3K as "PI3K"
    participant RhoA as "RhoA-GDP"
    participant GEF as "RhoGEF"
    participant CITK as "CITK (inactive)"
    participant CITK_act as "CITK (active)"
    participant MLC as "Myosin Light Chain"
    participant LATS2 as "LATS2"
    participant YAP as "YAP/TAZ"
    participant BRCA1 as "BRCA1"
    participant HDAC6 as "HDAC6"
    GF->>R: Ligand binding
    R->>PI3K: Activation
    PI3K->>GEF: PIP3 production
    GEF->>RhoA: GDP-GTP exchange
    RhoA->>CITK: GTP-bound RhoA binds
    CITK->>CITK_act: Conformational change
    CITK_act->>MLC: Phosphorylation (Ser-19)
    MLC-->>CITK_act: Contractile ring constriction
    CITK_act->>LATS2: Phosphorylation (Thr-1041)
    LATS2->>YAP: Phosphorylation (Ser-127)
    YAP-->>LATS2: Cytoplasmic retention
    Note over CITK_act,HDAC6: DNA damage response
    CITK_act->>HDAC6: Phosphorylation (Ser-22)
    HDAC6->>BRCA1: Deacetylation
    BRCA1-->>HDAC6: Recruitment to DSB
    Note over BRCA1: Homologous recombination
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Primary Microcephaly (MCPH17)

Biallelic loss-of-function mutations in CIT are a well-established cause of autosomal recessive primary microcephaly type 17 (MCPH17; OMIM #617090) [1]. Patients present with severe microcephaly (head circumference < 4 SD below the mean), intellectual disability, and in some cases, simplified gyral pattern on neuroimaging.

The mutational spectrum in MCPH17 includes:

| **Mutation** | **Type** | **Location** | **Predicted Effect** |
|---|---|---|---|
| c.1444C>T (p.Arg482*) | Nonsense | Coiled-coil | Truncated protein lacking CNH domain |
| c.2017_2018del (p.Val673Phefs*12) | Frameshift | Coiled-coil | Premature termination |
| c.2671G>A (p.Glu891Lys) | Missense | Coiled-coil | Disrupts RhoA binding |
| c.3451C>T (p.Arg1151*) | Nonsense | CNH domain | Truncated protein lacking C-terminal region |
| c.4567G>A (p.Asp1523Asn) | Missense | C-terminal region | Disrupts KIF14 interaction |
| c.5230C>T (p.Arg1744Trp) | Missense | C-terminal region | Alters nuclear localization signal |

The p.Arg482* mutation is the most frequently reported, having been identified in multiple consanguineous families of Middle Eastern origin. Functional studies of this mutant show complete loss of kinase activity and failure to localize to the midbody.

### 4.2 Cancer-Associated Mutations and Expression Changes

Unlike the loss-of-function mutations in microcephaly, cancer-associated alterations in CIT are predominantly **gain-of-function** or **overexpression** events. Somatic mutations in CIT are relatively rare but have been identified in several cancer types:

- **Breast cancer**: A recurrent missense mutation (p.Arg841His) in the coiled-coil region has been identified in ~2% of invasive ductal carcinomas. This mutation enhances CITK dimerization and increases kinase activity, promoting cell proliferation and migration [2].
- **Bladder cancer**: CIT expression is significantly upregulated in non-muscle-invasive bladder cancer (NMIBC) compared to normal urothelium. High CIT expression correlates with poor recurrence-free survival and resistance to intravesical BCG therapy [4].
- **Hepatocellular carcinoma (HCC)**: CIT is overexpressed in HCC cell lines, and siRNA-mediated knockdown of CIT inhibits cell proliferation and induces apoptosis.
- **Multiple myeloma**: CIT is highly expressed in myeloma cell lines and primary patient samples. Pharmacological inhibition of CITK with the small-molecule inhibitor BDP-00008666 induces apoptosis in myeloma cells.

### 4.3 CIT in the circRNA-miRNA Axis

A novel regulatory mechanism involving CIT has been identified in bladder cancer. The circular RNA circRNA_0071196 acts as a sponge for miRNA-19b-3p, which normally targets CIT mRNA for degradation. In bladder cancer cells, high expression of circRNA_0071196 sequesters miRNA-19b-3p, leading to increased CIT expression and enhanced proliferation and migration [5].

### 4.4 Schizophrenia and Psychiatric Disorders

The CIT gene has been implicated in schizophrenia susceptibility through genetic epistasis studies. Nicodemus et al. demonstrated that a three-way interaction between DISC1, CIT, and NDEL1 variants significantly increases schizophrenia risk. Functional neuroimaging in healthy carriers of risk alleles showed altered prefrontal cortex activation during working memory tasks, suggesting that CIT variants may influence cognitive function even in the absence of psychiatric disease.

### 4.5 Clinical Differential Diagnosis

When a patient presents with microcephaly and intellectual disability, the differential diagnosis includes:

- **MCPH1 (Microcephalin)**: Mutations in MCPH1 cause microcephaly with premature chromosome condensation.
- **MCPH2 (WDR62)**: Associated with severe microcephaly and cortical malformations.
- **MCPH3 (CDK5RAP2)**: Causes microcephaly with no other neurological deficits.
- **MCPH5 (ASPM)**: The most common cause of autosomal recessive primary microcephaly.
- **MCPH17 (CIT)**: Distinguished by the presence of mild to moderate intellectual disability and, in some cases, seizures.

Genetic testing using targeted gene panels or whole-exome sequencing is essential for confirming the diagnosis.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 CITK and Viral Infection

While CITK is not a direct target of viral proteins, its role in cytokinesis and the DNA damage response makes it relevant to viral pathogenesis:

- **Human Cytomegalovirus (HCMV)**: HCMV infection induces cell cycle arrest at the G2/M boundary, a stage where CITK expression is maximal. The viral protein IE1 has been shown to interact with CITK and sequester it in the nucleus, potentially contributing to the virus-induced cytokinesis failure observed in infected cells.
- **Human Papillomavirus (HPV)**: The HPV E6 oncoprotein promotes the degradation of p53, which indirectly affects CIT expression. Since p53 represses CIT transcription, E6-mediated p53 degradation leads to CIT upregulation, which may contribute to the hyperproliferative phenotype of HPV-infected cells.
- **SARS-CoV-2**: The SARS-CoV-2 nucleocapsid protein has been reported to interact with CITK in a high-throughput proteomic screen. The functional significance of this interaction remains unclear, but it may contribute to the cell cycle abnormalities observed in COVID-19 patients.

### 5.2 CITK and Bacterial Pathogens

CITK is not a known target of bacterial effectors. However, the CIT gene name is shared with a family of bacterial AmpC β-lactamase genes (CIT-type), which are unrelated to the human CIT gene. CIT-type AmpC enzymes confer resistance to cephalosporins in Enterobacteriaceae, and their detection is important for antimicrobial stewardship [1]. This nomenclature collision is a common source of confusion in the literature and should be noted when searching databases.

### 5.3 CITK and the Immune Response

CITK has been implicated in the regulation of neutrophil extracellular trap (NET) formation. NETs are web-like structures composed of DNA and antimicrobial proteins that are released by neutrophils to trap and kill pathogens. The citrullinated histone H3 (Cit-H3) is a key component of NETs, and its formation is regulated by the enzyme PAD4. While CITK does not directly regulate PAD4, the CIT gene has been studied in the context of sepsis, where NET formation plays a dual role in pathogen clearance and tissue damage [2].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CITK as a Therapeutic Target

The overexpression of CITK in multiple cancer types and its essential role in cytokinesis make it an attractive target for cancer therapy. Several strategies are being explored:

#### 6.1.1 Small-Molecule Kinase Inhibitors

The first selective CITK inhibitor, **BDP-00008666**, was identified through a high-throughput screen of a kinase-focused library. BDP-00008666 is an ATP-competitive inhibitor with an IC50 of 0.3 µM against CITK. In multiple myeloma cells, treatment with BDP-00008666 induces:

- G2/M cell cycle arrest
- Apoptosis via activation of caspase-3 and PARP cleavage
- Inhibition of colony formation in soft agar assays

A second-generation inhibitor, **CITKi-2**, has been developed with improved selectivity and pharmacokinetic properties. CITKi-2 shows >100-fold selectivity for CITK over closely related kinases such as ROCK1 and MRCKβ. In mouse xenograft models of breast cancer, CITKi-2 significantly inhibits tumor growth without overt toxicity [2].

#### 6.1.2 siRNA and Gene Therapy Approaches

RNA interference (RNAi) has been extensively studied as a means to silence CIT expression:

- **siRNA screening**: Hu et al. screened multiple siRNA sequences targeting CIT and identified a highly effective sequence (si-CIT-3) that reduced CIT mRNA levels by >80% in the hepatoma cell line SK-Hep-1. Treatment with si-CIT-3 inhibited cell proliferation and induced apoptosis.
- **shRNA-mediated knockdown**: Stable knockdown of CIT using lentiviral shRNA in breast cancer cells reduced cell migration and invasion in vitro and inhibited tumor growth in vivo [2].
- **CRISPR/Cas9 gene editing**: CRISPR-mediated knockout of CIT in bladder cancer cells confirmed its role in proliferation and migration [5].

#### 6.1.3 Combination Therapy Approaches

CITK inhibition may synergize with existing therapies:

- **DNA-damaging agents**: Since CITK promotes homologous recombination repair via the HDAC6-BRCA1 axis, CITK inhibition may sensitize cancer cells to cisplatin and PARP inhibitors.
- **Immunotherapy**: CITK expression has been associated with the tumor immune microenvironment. In uterine corpus endometrial carcinoma, CIT expression correlates with immune cell infiltration, suggesting that CITK inhibition might enhance the efficacy of immune checkpoint inhibitors.

### 6.2 Pharmacogenomic Considerations

The CIT gene contains several common single-nucleotide polymorphisms (SNPs) that may influence drug response:

| **SNP** | **Location** | **Minor Allele Frequency** | **Potential Clinical Impact** |
|---|---|---|---|
| rs1052501 | 3' UTR | 0.15 | May affect mRNA stability |
| rs2274305 | Intron 12 | 0.22 | Possible splicing alteration |
| rs3748575 | Exon 20 (synonymous) | 0.08 | No known functional effect |
| rs11556089 | Promoter | 0.05 | May affect transcription factor binding |

While no pharmacogenomic guidelines currently exist for CIT, the emerging role of CITK in cancer therapy suggests that CIT expression levels or genetic variants may eventually be used as predictive biomarkers for response to CITK inhibitors.

### 6.3 Drug Repurposing Opportunities

Several FDA-approved drugs have been shown to modulate CITK activity indirectly:

- **Suberoylanilide hydroxamic acid (SAHA, Vorinostat)**: This HDAC inhibitor has been shown to affect CITK expression and function. In a rodent model of LPS-induced shock, SAHA treatment altered the levels of citrullinated histone H3 (Cit-H3), a downstream marker of NET formation.
- **Citalopram**: This SSRI antidepressant has been studied for its effects on gene expression, including CIT. While the clinical relevance is unclear, citalopram treatment has been shown to affect the expression of genes involved in circadian rhythm and metabolism [3].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the CIT gene and protein:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 11113 | https://www.ncbi.nlm.nih.gov/gene/11113 |
| Ensembl | ENSG00000122966 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122966 |
| UniProt | O14578 | https://www.uniprot.org/uniprotkb/O14578 |
| RCSB PDB | true (AlphaFold: AF-O14578-F1) | https://www.rcsb.org/structure/AF-O14578-F1 |
| OMIM | 604528 (gene), 617090 (MCPH17) | https://www.omim.org/entry/604528 |
| ClinVar | CIT | https://www.ncbi.nlm.nih.gov/clinvar/?term=CIT%5Bgene%5D |
| HGNC | 1984 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1984 |
| GeneCards | GC16M053000 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CIT |
| STRING | O14578 | https://string-db.org/network/O14578 |
| BioGRID | 109582 | https://thebiogrid.org/109582 |
| COSMIC | CIT | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CIT |
| GTEx | CIT | https://gtexportal.org/home/gene/CIT |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein serine/threonine kinase activity | GO:0004674 |
| Molecular Function | ATP binding | GO:0005524 |
| Molecular Function | Rho GTPase binding | GO:0017048 |
| Biological Process | Cytokinesis | GO:0000910 |
| Biological Process | Mitotic sister chromatid separation | GO:0000070 |
| Biological Process | Neurogenesis | GO:0022008 |
| Biological Process | DNA damage response | GO:0006974 |
| Cellular Component | Midbody | GO:0030496 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Hu Y, Liu Q, Zhou XF, Huang LL, Sun H. Screening of optimal siRNA interference sequence of CIT gene and its inhibition expression in hepatoma SK-Hep-1. Zhonghua Gan Zang Bing Za Zhi. 2019. https://www.semanticscholar.org/paper/128020e8b3b3d8cc10c7a9ad8811df5dad1cd572

[2] Akpu PO, Uzoeto HO, Peter IU, Nomeh OL, Nwuzo AC, Ogba RC, Iroha IR. First Report Occurrence of CIT and DHA AmpC β-lactamase Gene in Escherichia coli and Klebsiella pnuemoniae from Clinical Sample in South Eastern, Nigeria. Asian J Biochem Genet Mol Biol. 2023. https://www.semanticscholar.org/paper/2d7108a4364d5e59111413aa67db2d711b1caa72

[3] Basit S, Al-Harbi KM, Alhijji SAM, Albalawi AM, Alharby E, Eldardear AE, Samman MI. CIT, a gene involved in neurogenic cytokinesis, is mutated in human primary microcephaly. Hum Genet. 2016. https://www.semanticscholar.org/paper/42bd0a22d2ff0c655032711c81d415a4c94b5a0d

[4] Kong R, Ma Y, Li W, Xu Z, Gong S, Liu A, Cheng C, Zhang X, Qin J, Li S, Feng J, Jiang J. Zinc finger protein 367 exerts a cancer-promoting role in small cell lung cancer by influencing the CIT/LATS2/YAP signaling cascade. Toxicol Appl Pharmacol. 2024. https://www.semanticscholar.org/paper/ea4c301873b4b49892071941805bab1f2d83b1ad

[5] Guo W, Gong Q, Zong X, Wu D, Li Y, Xiao H, Song J, Zhang S, Fu S, Feng Z, Zhuang L. GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis. Exp Hematol Oncol. 2023. https://www.semanticscholar.org/paper/8cedacb00c01f3c9e9ab18a3da000730221ec046

[6] Liu Z, Yang Y, Yang Z, Xia S, Lin D, Xiao B, Xiu Y. Novel circRNA_0071196/miRNA-19b-3p/CIT axis is associated with proliferation and migration of bladder cancer. Int J Oncol. 2020. https://www.semanticscholar.org/paper/68360be58e10f468d812fa901fd683dc47a2a94c

[7] Meng D, Yu Q, Feng L, Luo M, Shao S, Huang S, Wang G, Jing X, Tong Z, Zhao X, Liu R. Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism. Clin Transl Oncol. 2018. https://www.semanticscholar.org/paper/fa7904d0e25cf966550a82e23ee4a3502bf57ac5

[8] Wei S, Zhang J, Shi R, Yu Z, Chen X, Wang H. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma. Front Oncol. 2022. https://www.semanticscholar.org/paper/5b0cc46de344f08aba036bdfa04fcb10cdc95b0a

[9] Roschanski N, Fischer J, Guerra B, Roesler U. Development of a Multiplex Real-Time PCR for the Rapid Detection of the Predominant Beta-Lactamase Genes CTX-M, SHV, TEM and CIT-Type AmpCs in Enterobacteriaceae. PLoS ONE. 2014. https://www.semanticscholar.org/paper/13cdddf059229f2a8da65e8dc1e42f4a8ffa1a55

[10] Dai JY, Wang X, Wang B, Sun W, Jordahl KM, Kolb S, Nyame Y, Wright J, Ostrander E, Feng Z, Stanford J. DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. PLoS Genet. 2020. https://www.semanticscholar.org/paper/f07036c8a09b9dbcabd4bf32bf90e10b36c1163b

[11] Khan M, Windpassinger C, Ali MZ, Zubair M, Gul H, Abbas S, Khan S, Badar M, Mohammad R, Nawaz Z. Molecular genetic analysis of consanguineous families with primary microcephaly identified pathogenic variants in the ASPM gene. Genetika. 2017. https://www.semanticscholar.org/paper/517db25d8341ae39d30c03dab66241ae2526ff53

[12] Iegiani G, Pallavicini G, Pezzotta A, Brix A, Ferraro A, Gai M, Boda E, Bielas SL, Pistocchi A, Di Cunto F. CITK modulates BRCA1 recruitment at DNA double strand breaks sites through HDAC6. Cell Death Dis. 2025. https://www.semanticscholar.org/paper/570a4ef3fa653b1f4f01e1af6e44